아토시반 시장 규모는 2023년에 4억 2,200만 달러로 평가되며, 2024-2030년의 예측 기간 중 CAGR 11.5%로 성장하며, 2030년에는 8억 4,100만 달러에 달할 것으로 예측됩니다. 아토시반 시장은 임산부의 조산율, 다태임신, 감염성 질환, 당뇨병 및 고혈압 등 만성질환 증가로 인해 시장이 확대되고 있습니다. 세계의 아토시반 시장 보고서는 시장의 전반적인 평가를 제공합니다. 주요 부문, 동향, 시장 성장 촉진요인, 억제요인, 경쟁 구도 시장에서 중요한 역할을 하는 요인 등을 종합적으로 분석합니다.
세계 아토시반 시장의 정의
바소프레신 및 옥시토신 수용체 길항제인 아토시반은 합성 비펩티드 데사미노옥시토신 유사체입니다. 세포질내 칼슘 방출을 억제하고 프로스타글란딘 합성을 하향 조절하여 자궁 수축을 약화시키고 자궁 수용성을 증가시키는 능력이 있으므로 보조생식술 후 조산 예방 및 조산 중단의 목적으로 사용됩니다.
세계 아토시반 시장 개요
아토시반은 자궁근육 수축의 강력한 활성화제이며, 정상 분만과 조산의 시작에 매우 중요한 역할을 합니다. 조산율이 증가하고 있으며, 이는 아토시반 시장 확대에 박차를 가하고 있습니다. 임산부의 다태임신, 감염, 당뇨병, 고혈압 등 만성질환 증가로 인해 유병률이 증가하고 있습니다.
세계보건기구(WHO)의 추정에 따르면 매년 1,500만 명의 아기가 조산으로 태어나고 있으며, 이는 증가 추세에 있으며, 184개국에서 신생아의 5%에서 18%가 조산아로 태어나고 있습니다. 건강한 임신은 조산과 관련된 사망과 문제를 줄이는 데 큰 책임이 있습니다. 현대적이고 비용 효율적인 치료법을 사용하여 이러한 비극을 더 자주 피해야 합니다.
맞춤형 치료 동향이 아토시반 시장에 영향을 미치고 있습니다. 유전학 및 약물유전체학 연구는 아토시반 치료를 강화할 수 있는 환자별 특성을 파악하는 데 도움을 주고 있습니다. 또한 원격의료 및 원격 환자 모니터링과 같은 디지털 건강 툴은 아토시반의 투여 및 추적 방법을 변화시켜 환자의 치료 결과를 개선할 수 있습니다.
몇 가지 제한과 어려움이 시장 확대를 방해할 수 있습니다. 관련 규제 문제, 병원 인프라 부족, 농촌 지역의 불충분한 산모 관리 교육 등이 시장 확대에 제약이 되고 있습니다.
Atosiban Market size was valued at USD 422 Million in 2023 and is projected to reach USD 841 Million by 2030 , growing at a CAGR of 11.5% during the forecast period 2024-2030. The market for Atosiban is expanding due to rising rates of preterm delivery, numerous pregnancies, infections, and chronic illnesses like diabetes and high blood pressure among pregnant women. The Global Atosiban Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors playing a substantial role in the market.
Global Atosiban Market Definition
A competitive vasopressin and oxytocin receptor antagonist, Atosiban is a synthetic nonpeptide desamino-oxytocin analog. Because of its capacity to lessen contractions and increase uterine receptivity by reducing intracytoplasmic calcium release and downregulating prostaglandin synthesis, it is used after assisted reproduction to prevent preterm birth and to stop premature labor.
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
Global Atosiban Market Overview
Atosiban is a potent activator of myometrial contractions and is crucial at the start of both term and preterm labor. Preterm birth rates are rising, fueling the market expansion for Atosiban. Prevalence is fueled by increased multiple pregnancies, infections, and chronic illnesses, including diabetes and high blood pressure among pregnant women.
The World Health Organization estimates that 15 million babies are born preterm each year, which is increasing. Between 5% and 18% of newborns are born preterm in 184 nations. A healthy pregnancy is heavily responsible for reducing preterm birth-related fatalities and problems. With the use of modern, cost-effective therapies, these tragedies must be avoided more frequently.
The trend toward personalized treatment is impacting the market for Atosiban. Genetic and pharmacogenomic investigations are aiding the identification of patient-specific characteristics that can enhance Atosiban treatment. Additionally, digital health tools like telemedicine and remote patient monitoring alter how Atosiban is administered and tracked, leading to better patient outcomes.
Some limitations and difficulties may prevent the market from expanding. Related regulatory issues, a lack of hospital infrastructure, and insufficient prenatal care education in rural areas constrain the market's expansion.
The Global Atosiban Market is segmented on the basis of Type, Application, and Geography.
By Type
Injection
Concentrate
Based on the Type, The market is segmented into Injection and Concentrate. The Injection segment is anticipated to dominate the Global Atosiban market. The quick beginning of the effect of Atosiban injection is well established. It is helpful for instances where urgent tocolysis (inhibition of uterine contractions) is required since it can swiftly stop uterine contractions and delay preterm labor.
By Application
Hospitals
Online
Retail
Based on the Application, The market is segmented into Hospitals, Online, and Retail. The Hospitals segment is anticipated to dominate the Global Atosiban market. Most of the time, hospitals employ Atosiban, especially in labor and delivery or maternity wards. It is given intravenously by medical personnel to expectant mothers going through preterm labor.
By Geography
North America
Europe
Asia Pacific
Rest of the world
Based on the Regional Analysis, Global Atosiban is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America will hold the largest Global Atosiban market as preterm birth is still a significant healthcare concern. In recent years, preterm birth rates have increased in the area. This pattern has increased demand for medications such as Atosiban, which postpone preterm labor and lessen the risks of premature birth.
The "Global Atosiban Market" study report will provide valuable insight emphasizing the global market. The major players in the market are
Pfizer, Emcure Pharmaceuticals, Teva API, Ferring Pharmaceuticals, Sun Pharma, Shanghai Soho-Yiming Pharmaceuticals, EVER Pharma, Hangzhou Longshine Bio-Tech, Cayman Chemical, Neore Pharmaceutical, Hikma Pharmaceuticals, Lupin Pharmaceuticals, Bachem Group, Transo-Pharm Handels-GmbH, Rochem International Inc, Piramal Pharma Solutions.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.
Ace Matrix Analysis
The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features and innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories
Active, Cutting Edge, Emerging, and Innovators.
Market Attractiveness
The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Atosiban Market. We cover the major impacting factors driving the industry growth in the given region.
Porter's Five Forces
The image provided would further help to get information about Porter's five forces framework, providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape in the Global Atosiban Market, gauge the attractiveness of a certain sector, and assess investment possibilities.